I
immanentq
Is it acceptable to re-label or over-label a drug product? We are a small pharmaceutical manufacturing facility in the US. My manager and I have had a long standing, unresolved discussion as to whether it is within compliance to over-label a drug product. I say "No". The only reference I have ever found was with regard to medical devices stating that the practice was "discouraged". Does anyone have a FDA reference that will put this discussion to rest?